Lupus

EMD Serono previously announced that its CLE cohort had met its primary endpoint while its SLE cohort failed to follow suit.

A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.

The filing acceptance is based on positive data from the phase 3 REGENCY study. A decision on the approval is expected by October 2025.

Use of obinutuzumab was associated with significant improvements in complete renal response rate and markers of disease activity in active lupus nephritis.

ADI-001 now has FDA Fast Track Designation for relapsed/refractory lupus nephritis and systemic lupus erythematosus with extrarenal involvement.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.

Patients in the anifrolumab arm also had lower rates of damage accrual.

Hypovitaminosis D was more prevalent in patients with lupus nephritis compared to patients with systemic lupus erythematosus without kidney disease.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

Those with limited health literacy had higher disease activity and more SLE damage.

The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

Two patients with autoimmune diseases from 2 phase ½ RESET trials had complete B cell depletion within 15 days post-infusion with CABA-201 and needed no additional medication.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.